Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

June 23, 2020June 23, 2020

Recommendation Against PSA Routine Screening May Have Contributed to Higher Rates of Advanced PC

News

The U.S. rates of advanced prostate cancer continued to rise in men 50 and older after the U.S. Preventive Services Task Force (USPSTF) recommended in 2012 against prostate-specific antigen ... Read more

June 11, 2020June 11, 2020

Xtandi Plus ADT Bolsters Survival in High-risk Patients, Phase 3 Trial Finds

News

Adding Xtandi (enzalutamide) to standard androgen deprivation therapy (ADT) significantly prolonged life by nearly a year for men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), final data from a ... Read more

March 23, 2020April 15, 2020

Combining Two Biopsy Methods Improves PC Diagnosis, Study Shows

News

Combining two methods of prostate biopsy — using one guided by magnetic resonance imaging (MRI) along with conventional ultrasound-guided biopsy — results in a more accurate detection of clinically ... Read more

March 9, 2020March 9, 2020

Prolaris Test Predicts Which PC Patients Benefit from Combo Therapy, Study Finds

News

Myriad Genetics’ Prolaris — a genetic test that predicts the aggressiveness of prostate cancer — can identify which men with intermediate or high-risk prostate cancer will benefit from combining ... Read more

March 4, 2020March 4, 2020

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

News

A genetic test, called Decipher Prostate RP, can help to identify those prostate cancer patients with a relapse after surgery who will benefit most by adding androgen deprivation therapy (ADT) to radiation ... Read more

February 27, 2020February 27, 2020

Decipher GRID ‘Signature’ Predicts Chemo Benefits in HSPC, Research Shows

News

Decipher Bioscience’s proprietary artificial intelligence platform, Decipher GRID, one of the world’s largest urologic cancer genomic databases, can be used to identify subtypes of prostate cancer and predict which ... Read more

February 19, 2020February 19, 2020

Onvansertib’s Addition Aids Responses to Zytiga Even in Resistant Patients, New Trial Data Show

News

Trovagene’s investigational oral therapy onvansertib helps overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), latest data from a Phase 2 clinical trial show. These results also ... Read more

February 11, 2020February 13, 2020

Xtandi Significantly Improves Overall Survival in Men with High-risk CRPC, Phase 3 Final Data Show

News

Treatment with Xtandi (enzalutamide) significantly extends the lives of men with high-risk, non-metastatic castration-resistant prostate cancer (CRPC), according to final data from a Phase 3 clinical trial. Developed by Pfizer and Astellas Pharma, ... Read more

January 23, 2020January 23, 2020

Exelixis to Expand Group of mCRPC Patients in Phase 1b Trial Testing Cabometyx-Tecentriq Combo

News

Exelixis will expand its Phase 1b clinical trial evaluating a combination of Cabometyx (cabozantinib) with Tecentriq (atezolizumab) to include more patients with metastatic castration-resistant prostate cancer (mCRPC), based on ... Read more

January 16, 2020January 16, 2020

Rubraca Granted FDA Priority Review for Advanced Prostate Cancer with BRCA Mutations

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Clovis Oncology’s application seeking approval of Rubraca (rucaparib) for treating men with recurrent metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations. The priority review ... Read more

Pin It on Pinterest